Food and Drug Administration (FDA) has approved the use of respiratory syncytial virus immune globulin (RespiGam [TM]) to prevent RSV infection in infants at high risk of complications from the illness.
Respiratory syncytial virus immune globulin has been shown to prevent or attenuate RSV lower respiratory tract infection in infants under 24 months of age with BPD or who were born prematurely ([is less than or equal to] 35 weeks gestation).